News - Pharmaceutical
Ohr Pharmaceutical Provides Update to Shareholders on 2012 ...
27 December 2012
27, 2012 /PRNewswire/ -- Ohr Pharmaceutical Inc., a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets, announced today that it has published a letter to shareholders ...
Click on the link to read the full article at PR Newswire (press release) (This link will open in a new window)Celator commences third phase of leukemia study CPX-351
27 December 2012
Celator Pharmaceuticals has commenced patient enrollment in the phase-III study of CPX-351 in untreated high-risk acute myeloid leukemia (AML). The open-label trial is designed to assess CPX-351 (cytarabine:daunorubicin) liposome injection compared to ...
Click on the link to read the full article at Pharmaceutical Business Review (This link will open in a new window)Biomarin Pharmaceutical Inc. Files SEC Form 4, Statement of Changes in ...
26 December 2012
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Biomarin Pharmaceutical Inc. (Form 4) ...
Click on the link to read the full article at Equities.com (This link will open in a new window)Raptor Pharmaceutical: FDA Delay Is A Near-Term Negative, But Immaterial ...
26 December 2012
(By Mani) Raptor Pharmaceutical Corp. (NASDAQ: RPTP) said the FDA delayed the Prescription Drug User Fee Act (PDUFA) date by three months from January 30 to April 30 for Procysbi. Although the delay is a near-term negative event, it would not impact ...
Click on the link to read the full article at iStockAnalyst (This link will open in a new window)Court mistaken in ruling on advertising of drugs
26 December 2012
The U.S. Food and Drug Administration's regulatory system exists for a reason: to make sure that pharmaceutical drugs are safe for consumers. Obtaining approval for a new prescription medication can be difficult and can take years and heavy investment ...
Click on the link to read the full article at Milwaukee Journal Sentinel (This link will open in a new window)Vision of pharmaceutical co-operation
25 December 2012
Pharmaceutical packaging manufacturer Bausch + Str
Click on the link to read the full article at Vision Systems Design (This link will open in a new window)Beverly pharmaceutical company claims it's at leading edge of research on new ...
24 December 2012
Beverly biopharmaceutical company Cellceutix Corp. on Monday said a cancer drug it is testing in clinical trials is more advanced than similar treatments under development by larger companies that featured in The New York Times Sunday. Merck & Co.
Click on the link to read the full article at Boston Globe (This link will open in a new window)AIMM, Cosmo Pharmaceuticals join forces to develop gastrointestinal therapy
24 December 2012
Therapeutic antibody company AIMM Therapeutics has collaborated with Italy-based Cosmo Pharmaceuticals to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases, including colon carcinoma. As part of the agreement, Cosmo ...
Click on the link to read the full article at Pharmaceutical Business Review (This link will open in a new window)US FDA grants fast track status to LX1033
24 December 2012
Lexicon Pharmaceuticals has won Fast Track status from the US FDA to develop LX1033, an orally-delivered small molecule drug candidate to treat diarrhea-predominant irritable bowel syndrome (IBS-d). Fast Track facilitates the development and expedites ...
Click on the link to read the full article at Pharmaceutical Business Review (This link will open in a new window)Finox submits r-FSH biosimilar MAA to EMA
24 December 2012
Select a Pharmaceutical sector, ------------------------, Fine & Speciality Chemicals, Manufacturing, Process & Production, OTC, ------------------------, Drug Delivery, Drug Discovery & Development, ------------------------, Clinical Trials, Contract ...
Click on the link to read the full article at Pharmaceutical Business Review (This link will open in a new window)
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
